Contact Us

The assessment made available on the Mave website does not create a doctor-patient relationship between the individual completing the assessment and Mave. CareValidate Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the Mave assessment determine if the individual is screened out of eligibility for GLP-1 medication, and a CareValidate Health clinician will meet with the individual after checkout to determine if they qualify for a prescription. CareValidate Health clinicians retain the sole discretion to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire and every 3–4 weeks thereafter. Results from compounded medications available through the Mave platform may vary and may be affected by an individual's adherence to the program and their clinician's recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider's medical judgment, informed by a telehealth consultation and medical history. We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits. Mave does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Results vary based on starting weight and program adherence. Inches lost may include hips, waist, chest, thighs, and arms in the first month. Patients exercised regularly and followed a reduced-calorie diet. Individual results are not typical and may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Mave patients typically experience 1–2 lbs per week weight loss after 4 weeks, combined with a healthy diet and exercise. Consult a healthcare professional before using any medication or starting a weight loss program. Based on average weight loss reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, alongside reduced calorie intake and increased physical activity.

Medication may be included in the cost of the Mave program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this site are the property of their respective owners. Medical treatment is provided by "CareGLP Affiliated P.C.s" and CareValidate Health, affiliated networks of medical professional corporations and associations. No data, photos, claims, or other information presented are derived from clinical trials or public studies and are representative of Mave patient experience only.

*The assessment made available on the Mave website does not create a clinician-patient relationship between the individual completing the assessment and Mave. Mave is not a provider of medical services. Mave acts primarily as a technology platform to connect you with professional clinicians who may be available to provide you with non-emergency care. Such providers include JMP Medical, Bask Health, and certain other medical groups (collectively, the “Providers”). The Providers include a network of US-licensed clinicians that adhere to rigorous medical protocols designed for patient safety and have established exclusionary criteria to determine if an individual does not qualify for GLP-1s. Each Mave assessment will be reviewed by a clinician who will determine if the individual is eligible for GLP-1 medicationand qualifies for a prescription. Provider clinicians retain the decision to prescribe compounded GLP-1s to patients.

All claims and benefits on this website refer to self-reported data from Mave customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from compounded medications found on the Mave platform may vary and be affected by an individual's adherence to the program and their clinician's recommendations. Although compounded GLP-1s are produced in facilities that are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed clinician's medical judgment, which is informed by a telehealth consultation and medical history.

How can we help?

Reach us directy

GENERAL INQUIRIES

CUSTOMER SUPPORT

B2B INQUIRIES

Ready to Stop Food Cravings? Get $150 OFF your prescription instantly!